BORA - UiB

Bergen Open Research Archive

Browsing by Author "Knappskog, Stian"

Bergen Open Research Archive

Browsing by Author "Knappskog, Stian"

Sort by: Order: Results:

  • Lønning, Per Eystein; Chrisanthar, Ranjan; Staalesen, Vidar; Knappskog, Stian; Lillehaug, Johan (Journal article; Peer reviewed, BioMed Central, 2007-12-20)
  • Berge, Elisabet Ognedal; Knappskog, Stian; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, Springer, 2011-01-21)
    Germline mutations affecting the retinoblastoma gene (RB1) predispose to inherited retinoblastomas but also other malignancies, including breast cancer. While somatic RB1 mutations have been detected in different malignancies, ...
  • Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet Ognedal; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise; Engebretsen, Lars Fredrik; Lillehaug, Johan; Lønning, Per Eystein (Journal article; Peer reviewed, Public Library of Science, 2008-08-26)
    Background: Chemoresistance is the main obstacle to cure in most malignant diseases. Anthracyclines are among the main drugs used for breast cancer therapy and in many other malignant conditions. Single parameter analysis ...
  • Bjørnslett, Merete; Knappskog, Stian; Lønning, Per Eystein; Dørum, Anne (Peer reviewed; Journal article, BioMed Central, 2012-10-05)
    Background: While BRCA mutation carriers possess a 20-40% lifetime risk of developing ovarian cancer, knowledge about genetic modifying factors influencing the phenotypic expression remains obscure. We explored the ...
  • Straume, Anne Hege; Knappskog, Stian; Lønning, Per Eystein (Journal article, Elsevier, 2014-02-18)
    Breast cancers reveal elevated E2 levels compared to plasma and normal breast tissue. Previously, we reported intra-tumour E2 to be negatively correlated to transcription levels of 17β-HSD2 but positively correlated to ...
  • Berge, Elisabet Ognedal; Knappskog, Stian; Geisler, Stephanie; Staalesen, Vidar; Pacal, Marec; Børresen-Dale, Anne-Lise; Puntervoll, Pål; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, BioMed Central, 2010-07-01)
    Background The tumor suppressor pRb plays a key role regulating cell cycle arrest, and disturbances in the RB1 gene have been reported in different cancer forms. However, the literature reports contradictory findings with ...
  • Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein (Journal article, BioMed Central, 2012-03-15)
    Introduction: Mutations affecting p53 or its upstream activator Chk2 are associated with resistance to DNAdamaging chemotherapy in breast cancer. ATM (Ataxia Telangiectasia Mutated protein) is the key activator of p53 ...
  • Knappskog, Stian; Gansmo, Liv B.; Romundstad, Pål; Bjørnslett, Merete; Trovik, Jone; Lønning, Per Eystein; Salvesen, Helga B. (Peer reviewed; Journal article, Public Library of Science, 2012-04-30)
    The MDM2 proto-oncogene plays a key role in central cellular processes like growth control and apoptosis, and the gene locus is frequently amplified in sarcomas. Two polymorphisms located in the MDM2 promoter P2 have been ...
  • Knappskog, Stian; Gansmo, Liv Beathe; Dibirova, Khadizha; Metspalu, Andres; Cybulski, Cezary; Peterlongo, Paolo; Aaltonen, Lauri; Vatten, Lars Johan; Romundstad, Pål Richard; Hveem, Kristian; Devilee, Peter; Evans, Gareth D; Lin, Dongxin; Van Camp, Guy; Manolopoulos, Vangelis G; Osorio, Ana; Milani, Lili; Ozcelik, Tayfun; Zalloua, Pierre; Mouzaya, Francis; Bliznetz, Elena; Balanovska, Elena; Pocheshkova, Elvira; Kucinskas, Vaidutis; Atramentova, Lubov; Nymadawa, Pagbajabyn; Titov, Konstantin; Lavryashina, Maria; Yusupov, Yuldash; Bogdanova, Natalia; Koshel, Sergey; Zamora, Jorge; Wedge, David C.; Charlesworth, Deborah; Dörk, Thilo; Balanovsky, Oleg; Lønning, Per Eystein (Journal article, Impact Journals, 2014-04-18)
    The MDM2 promoter SNP285C is located on the SNP309G allele. While SNP309G enhances Sp1 transcription factor binding and MDM2 transcription, SNP285C antagonizes Sp1 binding and reduces the risk of breast-, ovary- and ...
  • Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjösne, Hans E.; Nysted, Arne; Lillehaug, Johan; Lønning, Per Eystein (Peer reviewed; Journal article, Public Library of Science, 2011-04-27)
    Background: TP53 mutations have been associated with resistance to anthracyclines but not to taxanes in breast cancer patients. The MDM2 promoter single nucleotide polymorphism (SNP) T309G increases MDM2 activity and may ...
  • Eikesdal, Hans Petter; Knappskog, Stian; Aas, Turid; Lønning, Per Eystein (Journal article, Informa Healthcare, 2014-10)
    Background: Before the advent of neoadjuvant chemotherapy, radiotherapy and surgery alone were associated with a high risk of uncontrolled locoregional relapses in locally advanced breast cancer (LABC).Material ...

Search BORA

Browse

My Account